Sirolimus: Clinical Trials

86 trials of Sirolimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 completed, 20 unknown, 5 recruiting, 5 withdrawn. 86 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 486Completed 51, Unknown 20, Recruiting 5, Withdrawn 5, Terminated 4, Active not recruiting 1

Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus

Trials (filtered) newest first · largest first

All 86 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy
Phase 4RecruitingSarepta Therapeutics, Inc.202026-11-302026-11-12
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer
Phase 4RecruitingDana-Farber Cancer Institute802026-04-232026-08-11
Effect of Sirolimus on Oocyte Quality in Women Undergoing IVF
Sirolimus (aka rapamycin) - Oocytes, Oocyte Competence
Phase 4RecruitingCenter for Human Reproduction202026-02-252026-11-13
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
Sirolimus, Placebo - Antiphospholipid (aPL)-Positive, Thrombocytopaenia
Phase 4RecruitingPeking University First Hospital842025-01-072026-06-30
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Sirolimus - Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
Phase 4RecruitingTongji Hospital2762024-01-012024-02-01
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
Sirolimus, Mycophenolate mofetil - Kidney Transplantation
Phase 4Active not recruitingChong Kun Dang Pharmaceutical2062021-11-192026-02-17
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
Percutaneous sirolimus, Oral sirolimus - Kaposiform Hemangioendothelioma, Tufted Angioma
Phase 4UnknownChildren's Hospital of Fudan University752021-10-222024-03-15
Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.
Sirolimus Tab., Mycophenolate Mofetil Cap./Tab. - Kidney Transplantation
Phase 4UnknownChong Kun Dang Pharmaceutical1582021-01-012021-01-08
Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
Sirolimus Oral Product, propranolol - Hemangioendothelioma of Liver
Phase 4UnknownShanghai Children's Medical Center362020-07-012020-05-29
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
Sirolimus - Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome
Phase 4CompletedChildren's Hospital of Fudan University302020-07-012023-09-26
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
Sirolimus, Cyclosporine A - Pure Red Cell Aplasia, Acquired
Phase 4CompletedBing Han562020-07-012023-02-28
Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia
sirolimus and ATRA, sirolimus - Autoimmune Anemia
Phase 4WithdrawnPeking Union Medical College Hospital2020-04-202026-07-07
Immune Monitoring to Facilitate Belatacept Monotherapy
Allosure, Immunosuppression reduction, Trugraf - Kidney Transplant Rejection, Immunosuppression
Phase 4CompletedMassachusetts General Hospital172020-02-112023-12-04
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Sirolimus(0.8mg/m2), Sirolimus(0.7mg/m2) - Hemangioma, Kaposiform Hemangioendothelioma
Phase 4CompletedChildren's Hospital of Fudan University922019-05-012023-01-30
Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
sirolimus - Paroxysmal Nocturnal Hemoglobinuria
Phase 4UnknownPeking Union Medical College Hospital402019-04-012019-03-08
Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
Rapamycin - Peutz-Jeghers Syndrome
Phase 4UnknownPeking Union Medical College Hospital102018-09-162019-01-23
Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
Rapamycin - Blue Rubber Bleb Nevus Syndrome, Venous Malformation
Phase 4UnknownPeking Union Medical College Hospital202018-07-312018-12-19
Sirolimus Treatment for Refractory PRCA
Sirolimus - Pure Red Cell Aplasia
Phase 4CompletedBing Han642018-02-012021-07-06
Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis
rapamycin - Uterine Fibroids
Phase 4UnknownPeking Union Medical College Hospital252018-01-012018-04-18
Study of Sirolimus in CTD-TP in China
Sirolimus - Connective Tissue Diseases, Thrombocytopenia
Phase 4UnknownPeking Union Medical College Hospital202017-09-212019-04-17

Showing 20 of 86. Sign in to see all of them.

Conditions studied

Renal Insufficiency (7)  ·  Kidney Diseases (4)  ·  Graft vs Host Disease (3)  ·  Kaposiform Hemangioendothelioma (3)  ·  Kidney Failure, Chronic (3)  ·  Rejection, Psychology (3)  ·  Skin Neoplasms (3)  ·  Coronary Artery Disease (2)  ·  Coronary Restenosis (2)  ·  Cytomegalovirus Infections (2)  ·  Delayed Graft Function (2)  ·  Hereditary Sensory and Autonomic Neuropathies (2)  ·  Kasabach-Merritt Syndrome (2)  ·  Pulmonary Fibrosis (2)  ·  Red-Cell Aplasia, Pure (2)

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer (12)  ·  Peking Union Medical College Hospital (6)  ·  Children's Hospital of Fudan University (3)  ·  National Taiwan University Hospital (3)  ·  University Hospital, Basel, Switzerland (3)  ·  Bing Han (2)  ·  Chong Kun Dang Pharmaceutical (2)  ·  Hoffmann-La Roche (2)  ·  Hospital do Rim e Hipertensão (2)  ·  Mayo Clinic (2)  ·  Northwestern University (2)  ·  Seung-Jung Park (2)  ·  University of Cincinnati (2)  ·  University of Maryland, Baltimore (2)  ·  University of Miami (2)

Countries

United States (27)  ·  China (15)  ·  South Korea (7)  ·  Germany (6)  ·  Brazil (5)  ·  Canada (5)  ·  Spain (5)  ·  Australia (4)  ·  Switzerland (4)  ·  Taiwan (4)  ·  Argentina (2)  ·  Austria (2)  ·  Belgium (2)  ·  Czechia (2)  ·  France (2)

Top investigators

Kai Li, MD, PhD (2)  ·  Mark D. Stegall, M.D. (2)  ·  Seung-Jung Park, MD, PhD (2)  ·  A. Tarik Kizilisik, M.D. (1)  ·  Abdolreza Haririan, MD, MPH (1)  ·  Adnan Kastrati, MD (1)  ·  Albert Heim, PD Dr. (1)  ·  Aleksandra Kukula, MD (1)  ·  Alfredo E Rodriguez, MD PhD FACC (1)  ·  Anke Schwarz, Prof. Dr. (1)

Results publications

PMID 19208097, PMID 19670189, PMID 24363761, PMID 26504182, PMID 27881371, PMID 10221490, PMID 10798738, PMID 12438948, PMID 12761269, PMID 14742989, PMID 14742990, PMID 15302787, PMID 15660173, PMID 15899725, PMID 16468960, PMID 16570006, PMID 18431244, PMID 18497677, PMID 19714613, PMID 19926058, PMID 19926370, PMID 20449934, PMID 20833822, PMID 21401720, PMID 21981661, PMID 22109997, PMID 22420843, PMID 22776430, PMID 23140536, PMID 23370547, PMID 24266855, PMID 25083614, PMID 26465152, PMID 26817280, PMID 28810721, PMID 29982851, PMID 31561278, PMID 32022990, PMID 32030447, PMID 33200217, PMID 37046380, PMID 37160872, PMID 37525373, PMID 38481209, PMID 40197799

NIH funding

2004 (1)